217 related articles for article (PubMed ID: 18298349)
1. Serum levels of the osteoprotegerin, receptor activator of nuclear factor kappa-B ligand, metalloproteinase-1 (MMP-1) and tissue inhibitors of MMP-1 levels are increased in men 6 months after acute myocardial infarction.
Halapas A; Zacharoulis A; Theocharis S; Karavidas A; Korres D; Papadopoulos K; Katopodis H; Stavropoulou A; Lembessis P; Xiromeritis C; Zacharoulis A; Koutsilieris M
Clin Chem Lab Med; 2008; 46(4):510-6. PubMed ID: 18298349
[TBL] [Abstract][Full Text] [Related]
2. Osteoprotegerin/RANK/RANKL axis in cardiac remodeling due to immuno-inflammatory myocardial disease.
Liu W; Feng W; Wang F; Li W; Gao C; Zhou B; Ma M
Exp Mol Pathol; 2008 Jun; 84(3):213-7. PubMed ID: 18417124
[TBL] [Abstract][Full Text] [Related]
3. Serum levels of osteoprotegerin and RANKL in patients with ST elevation acute myocardial infarction.
Crisafulli A; Micari A; Altavilla D; Saporito F; Sardella A; Passaniti M; Raffa S; D'anneo G; Lucà F; Mioni C; Arrigo F; Squadrito F
Clin Sci (Lond); 2005 Oct; 109(4):389-95. PubMed ID: 15926884
[TBL] [Abstract][Full Text] [Related]
4. Elevated serum receptor activator of NFkappaB ligand (RANKL), osteoprotegerin (OPG), matrix metalloproteinase (MMP)3, and ProMMP1 in patients with juvenile idiopathic arthritis.
Sarma PK; Misra R; Aggarwal A
Clin Rheumatol; 2008 Mar; 27(3):289-94. PubMed ID: 17703334
[TBL] [Abstract][Full Text] [Related]
5. Interrelationship of circulating matrix metalloproteinase-9, TNF-α, and OPG/RANK/RANKL systems in COPD patients with osteoporosis.
Zhang PF; Pan L; Luo ZY; Zhao HJ; Cai SX
COPD; 2013 Dec; 10(6):650-6. PubMed ID: 23845033
[TBL] [Abstract][Full Text] [Related]
6. Dysregulated atrial gene expression of osteoprotegerin/receptor activator of nuclear factor-κB (RANK)/RANK ligand axis in the development and progression of atrial fibrillation.
Cao H; Wang J; Xi L; Røe OD; Chen Y; Wang D
Circ J; 2011; 75(12):2781-8. PubMed ID: 22001292
[TBL] [Abstract][Full Text] [Related]
7. Dysregulated osteoprotegerin/RANK ligand/RANK axis in clinical and experimental heart failure.
Ueland T; Yndestad A; Øie E; Florholmen G; Halvorsen B; Frøland SS; Simonsen S; Christensen G; Gullestad L; Aukrust P
Circulation; 2005 May; 111(19):2461-8. PubMed ID: 15883214
[TBL] [Abstract][Full Text] [Related]
8. Relationship between circulating serum osteoprotegerin and total receptor activator of nuclear κ-B ligand levels, triglycerides, and coronary calcification in postmenopausal women.
Poornima IG; Mackey RH; Buhari AM; Cauley JA; Matthews KA; Kuller LH
Menopause; 2014 Jul; 21(7):702-10. PubMed ID: 24473535
[TBL] [Abstract][Full Text] [Related]
9. Osteoprotegerin/RANKL system imbalance in active polyarticular-onset juvenile idiopathic arthritis: a bone damage biomarker?
Spelling P; Bonfá E; Caparbo VF; Pereira RM
Scand J Rheumatol; 2008; 37(6):439-44. PubMed ID: 18802807
[TBL] [Abstract][Full Text] [Related]
10. Activation of the receptor activator of the nuclear factor-κB ligand pathway during coronary bypass surgery: comparison between on- and off-pump coronary artery bypass surgery procedures.
Galeone A; Brunetti G; Rotunno C; Oranger A; Colucci S; de Luca Tupputi Schinosa L; Zallone A; Grano M; Paparella D
Eur J Cardiothorac Surg; 2013 Aug; 44(2):e141-7. PubMed ID: 23671202
[TBL] [Abstract][Full Text] [Related]
11. Potential role of the OPG/RANK/RANKL axis in prostate cancer invasion and bone metastasis.
Li X; Liu Y; Wu B; Dong Z; Wang Y; Lu J; Shi P; Bai W; Wang Z
Oncol Rep; 2014 Dec; 32(6):2605-11. PubMed ID: 25333856
[TBL] [Abstract][Full Text] [Related]
12. The Relationship between Serum and Gene Expression Levels of RANK, RANKL and Osteoprotegerin Inflammatory Pathway with Unstable Angina: A Case-control Study.
Farrokhian A; Miraftab M; Chenari M; Akbari H; Nikoueinejad H; Naimi E
Iran J Allergy Asthma Immunol; 2021 Aug; 20(4):473-483. PubMed ID: 34418901
[TBL] [Abstract][Full Text] [Related]
13. OPG/RANK/RANKL signaling axis in patients with type I diabetes: Associations with parathormone and vitamin D.
Karalazou P; Ntelios D; Chatzopoulou F; Fragou A; Taousani M; Mouzaki K; Galli-Tsinopoulou A; Kouidou S; Tzimagiorgis G
Ital J Pediatr; 2019 Dec; 45(1):161. PubMed ID: 31823791
[TBL] [Abstract][Full Text] [Related]
14. IL-17 induces myocardial fibrosis and enhances RANKL/OPG and MMP/TIMP signaling in isoproterenol-induced heart failure.
Feng W; Li W; Liu W; Wang F; Li Y; Yan W
Exp Mol Pathol; 2009 Dec; 87(3):212-8. PubMed ID: 19527710
[TBL] [Abstract][Full Text] [Related]
15. [The relationships between changes of serum osteoprotegerin, nuclear factor-kappa B ligand receptor activator, and age, menopause, bone biochemical markers and bone mineral densities in women aged 20 - 75].
Liu JM; Zhao HY; Ning G; Zhao YJ; Chen Y; Zhang LZ; Xu MY; Chen JL
Zhonghua Nei Ke Za Zhi; 2004 Jun; 43(6):447-50. PubMed ID: 15312444
[TBL] [Abstract][Full Text] [Related]
16. CLINICAL Review #: the role of receptor activator of nuclear factor-kappaB (RANK)/RANK ligand/osteoprotegerin: clinical implications.
Vega D; Maalouf NM; Sakhaee K
J Clin Endocrinol Metab; 2007 Dec; 92(12):4514-21. PubMed ID: 17895323
[TBL] [Abstract][Full Text] [Related]
17. Serum levels of osteoprotegerin and receptor activator of nuclear factor-kappaB ligand as markers of periprosthetic osteolysis.
Granchi D; Pellacani A; Spina M; Cenni E; Savarino LM; Baldini N; Giunti A
J Bone Joint Surg Am; 2006 Jul; 88(7):1501-9. PubMed ID: 16818976
[TBL] [Abstract][Full Text] [Related]
18. Periodontal ligament cells under intermittent tensile stress regulate mRNA expression of osteoprotegerin and tissue inhibitor of matrix metalloprotease-1 and -2.
Tsuji K; Uno K; Zhang GX; Tamura M
J Bone Miner Metab; 2004; 22(2):94-103. PubMed ID: 14999519
[TBL] [Abstract][Full Text] [Related]
19. Identification of the osteoprotegerin/receptor activator of nuclear factor-kappa B ligand system in gingival crevicular fluid and tissue of patients with chronic periodontitis.
Lu HK; Chen YL; Chang HC; Li CL; Kuo MY
J Periodontal Res; 2006 Aug; 41(4):354-60. PubMed ID: 16827732
[TBL] [Abstract][Full Text] [Related]
20. The effect of zoledronic acid on serum dickkopf-1, osteoprotegerin, and RANKL in patients with Paget's disease of bone.
Polyzos SA; Anastasilakis AD; Efstathiadou Z; Kita M; Litsas I; Avramidis A; Arsos G; Moralidis E; Gerou S; Pavlidou V; Papatheodorou A; Terpos E
Horm Metab Res; 2009 Nov; 41(11):846-50. PubMed ID: 19670154
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
